医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GC Pharma Reports Q1 2021 Results

2021年04月29日 AM10:27
このエントリーをはてなブックマークに追加


 

YONGIN, South Korea

GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for the three months ended 31 March 2021.

First-Quarter Reported Results(1)

Key Figures(1)

Q1 2021

Growth(2)

Total revenues

KRW 282.2 billion

-8.3%

Operating profit

KRW 5.0 billion

-18.0%

K-IFRS profit after taxation

KRW 17.5 billion

T/P

(1)

 

Results from continuing operations (Green Cross MS’ blood bag business has been classified as discontinued operations)

(2)

 

Results and percentages compare to equivalent 2020 period

Financial Highlights

  • Delivered total revenue decline of 8.3% KRW 282.2 billion (2019 Q1: 307.8 billion), and operating profit decreased 18.0% to KRW 5.0 billion (2020 Q1: 6.1 billion) in the first quarter.
  • Unconsolidated revenues temporal setback due to termination of in-licence product distribution and vaccine’s international shipping schedule changes
  • Maintain double-digit growth in consolidated subsidiaries, including Green Cross MS, Green Cross LabCell and Green Cross Wellbeing
  • S/H Flu Vx sales to be reflected in the second quarter unlike prior year, Vx sales expected to be stronger in second half of the year
  • Int. sales of Hunterase sales up 412%, as its initial performance in Japan and China was reflected
  • In spite of gross margin profit growth 4%p driven by COGs improvement, operating profit impacted by SG&A+R&D cost maintain prior year level

About GC Pharma

GC Pharma is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, GC Pharma is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions more than half a century. Green Cross Corporation updates its corporate brand as GC Pharma in early 2018. Green Cross Corporation remains the company’s registered, legal name.

This release includes forward-looking statements, which express the current beliefs and expectations of GC Pharma’s management. Such statements speak only as of the date on which they are made and the company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210428006221/en/

CONTACT

Investor/Media Contact

HyunGoo Kang

+82 31 260 9382

gookang@greencross.com

WooSub Shin

+82 31 260 9397

isswoo@greencross.com

Yelin Jun

+82 31 270 1505

yelin@greencross.com

JiWoong Kim

+82 31 260 0759

yoholiday@greencross.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  •  Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
  • ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
  • ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial
  • 武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物
  • Masimo上市单例患者使用的rainbow® SuperSensor™